Efficacy and safety of Argatroban in patients with acute ischemic stroke: a systematic review and meta-analysis

ConclusionArgatroban can improve neurological deterioration, with a low incidence of adverse events such as bleeding and death, and general analysis showed no improvement in mRS. However, subgroup analysis suggests that compared to mono-antiplatelet therapy, combination therapy of Argatroban combined with antiplatelet therapy significantly reduced the incidence of END and improved mRS scores. After using Argatroban, there was no increase in the risk and mortality of intracranial hemorrhage and other bleeding sites.
Source: Frontiers in Neurology - Category: Neurology Source Type: research